ClinicalTrials.gg
Active, not recruitingNCT06627530COActionUpdated Oct 30, 2026

COACTION Trial - COmbination Androgen bloCkade in inTermediate to hIgh-risk prOstate caNcer

A Phase 4 interventional study of Darolutamide Oral Tablet and leuprorelin in Prostate Cancer, sponsored by Brazilian Clinical Research Institute. Active, not recruiting at 6 sites in Brazil. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Brazilian Clinical Research Institute · Phase 4, Interventional, and Treatment

How we know

Updated Oct 30, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 59 studies testing darolutamide in Prostatic Neoplasms — 29 open to participants now, 40 under way, 10 of them phase 3. darolutamide · Prostatic Neoplasms.

Planned enrollment
21st of 59
144 · median 80
Started
2025
with 3 others
Phase 4
4 of 59
3 open now
Primary completion
2026-12
later than 13 of 39 live
Registered
46th of 59
by date

Among the 59 studies testing darolutamide in Prostatic Neoplasms, this one is the 21st largest by planned enrollment, is one of 4 that started in 2025, is one of 4 in phase 4, reaches primary completion later than 13 of the 39 other live ones, and was the 46th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

29 of the 59 studies testing darolutamide in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

24 more — sign in →

By country, each count listing its studies:

All 29 open studies →

About darolutamide

darolutamide: first FDA approval 2019 (NUBEQA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing darolutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

A Randomized Trial of Neoadjuvant Leuprorelin, Darolutamide or Both Prior to Radical Prostatectomy for Intermediate or High-risk Prostate Cancer. Prospective, randomized, parallel group, open-label with blinded endpoint adjudication multicenter clinical trial.To assess, among patients with unfavorable intermediate to high-risk prostate cancer, whether a neoadjuvant combined treatment with leuprorelin (Leuprorelin) and darolutamide is superior to monotherapy in terms of complete or almost complete pathological response.A total of 144 patients with unfavorable intermediate to high-risk prostate cancer scheduled for radical prostatectomy with extended pelvic lymph node dissection will be randomized 1:1:1 to oral darolutamide, SC leuprorelin (Leuprorelin) or both (48 patients per arm) for 24 weeks.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • Prostate Cancer
  • Radical Prostatectomy
  • Darolutamide
  • Neoadjuvant
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men ≥18 years of age;
  • confirmed unfavorable intermediate or high/very high risk non (by conventional imaging) prostate adenocarcinoma intended for surgery without neuroendocrine differentiation or small cell features;
  • Unfavorable intermediate-risk:

    • ISUP grade 3, and/or > 50% positive cores and/or at least two intermediate-risk factors. Intermediate-risk factors:

      • Clinical tumor stage T2b or T2c (MRI based);
      • ISUP grade 2 or 3;
      • Prostate-specific antigen (PSA) level of 10-20 ng/mL.
  • High-risk or very high-risk:

    • ≥cT3a (MRI based) or ISUP 4-5 or PSA>20 ng/mL;
    • cN1.
  • 0-1;
  • Baseline testosterone > 230 ng/dL;
  • No prior prostate cancer treatment;
  • Sexually active male subjects must agree to use condoms as an effective barrier method and refrain from sperm donation, and/or their female partners of to use a method of effective , during the treatment with darolutamide and for 1 week after the end of treatment with darolutamide to prevent pregnancy;
  • Written .

Exclusion criteria

Exclusion Criteria:

  • Unresectable prostate cancer;
  • Histology of small cell carcinoma prostate cancer or adenocarcinoma with neuroendocrine features;
  • Any prior prostate cancer treatment;
  • Any active infection requiring IV antibiotics;
  • Known additional that has a life-expectancy \< 2 years;
  • Had any of the following within 6 months before randomization: stroke, myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, heart failure with Class Functional III or IV;
  • Uncontrolled severe hypertension as indicated by a resting systolic BP ≥ 180 mmHg or diastolic BP ≥ 110 mmHg despite medical management;
  • A gastrointestinal (GI) disorder or procedure which is expected to interfere significantly with absorption of darolutamide;
  • Inability to swallow oral medications;
  • Receipt of medications (e.g. finasteride, dutasteride) or agents that are likely to alter serum PSA levels within \<= 42 days or 5 half-lives prior to registration, whichever is shorter.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
144 participants (estimated)

Study arms

  • Experimental
    Darolutamide + ADT leuprorelin

    Drug: Darolutamide Oral Tablet · Drug: leuprorelin

  • Active comparator
    Darolutamide

    Drug: Darolutamide Oral Tablet

  • Active comparator
    Leuprorelin

    Drug: leuprorelin

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of patients with minimal residual disease

    Proportion of patients with minimal residual disease, defined as residual cancer burden (RCB) ≤ 0.25 cm3 (tumor volume ≤ 0.5 cm3 × tumor cellularity ≤ 50%) or complete pathological response, assessed by pathology of surgical specimen obtained from prostatectomy.

    Time frame: Patients are expected to undergo surgery after no more than 30 days after completion of the neoadjuvant regimen therapy, which will last for 24 weeks after randomization in all 3 groups.

Secondary outcomes

  1. Complete biochemical response assessed by serum PSA with the rate of PSA<0,2 ng/dL

    Time frame: 24 weeks

  2. Treatment emergent adverse events and serious adverse events.

    Time frame: 24 weeks

  3. PSA levels at 3 months after prostatectomy.

    Time frame: in 42 weeks

  4. Testosterone levels.

    Time frame: in 42 weeks

  5. Number of positive lymph nodes.

    Time frame: 30 weeks

  6. Number of positive surgical margins.

    Time frame: 30 weeks

  7. Perioperative complications.

    Time frame: 42 weeks

  8. Quality of life using IEEF5 and HRQoL questionnaires pre and post neoadjuvant treatment.

    Time frame: 42 weeks

  9. Downstaging (changes in TNM - Classification of Malignant Tumours stage) based on surgical specimen.

    Prostate cancer TNM (Classification of Malignant Tumours) staging AJCC (American Joint Committee on Cancer) UICC (Union for International Cancer Control) 8th edition

    Time frame: 30 weeks

07

Study locations

6 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Dec 2026, 22 months after the start.

Of 52 phase 4 interventional studies under Prostatic Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 67. This study's planned 22 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: primary completion Mar 2026 → Dec 2026 and completion Sep 2026 → Mar 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2024
First posted
Oct 4, 2024
StartActual
Feb 17, 2025
Primary completionEst.
Dec 2026was Mar 2026
CompletionEst.
Mar 2027was Sep 2026
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 2 sites removed
Show 2 added (2 Brazil)
  • Hospital Universitário Pedro Ernesto · Rio de Janeiro, Brazil
  • BP - A Beneficência Portuguesa de São Paulo · São Paulo, Brazil
Show 2 removed
  • Hospital Universitário Pedro Ernesto · Rio de Janeiro, Brazil
  • BP - A Beneficência Portuguesa de São Paulo · São Paulo, Brazil
Oct 30, 2026
Primary completion
Mar 2026→Dec 2026
Oct 30, 2026
Study completion
Sep 2026→Mar 2027
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    2 sites added, 2 sites removed
    Show 2 added (2 Brazil)
    • Hospital Universitário Pedro Ernesto · Rio de Janeiro, Brazil
    • BP - A Beneficência Portuguesa de São Paulo · São Paulo, Brazil
    Show 2 removed
    • Hospital Universitário Pedro Ernesto · Rio de Janeiro, Brazil
    • BP - A Beneficência Portuguesa de São Paulo · São Paulo, Brazil
    Primary completion Mar 2026→Dec 2026
    Study completion Sep 2026→Mar 2027

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06627530
Lead sponsor
Brazilian Clinical Research Institute
Collaborators
Bayer
Responsible party
Sponsor
First posted
Oct 4, 2024
Start date
Feb 17, 2025
Primary completion
Dec 2026 (estimated)
Completion
Mar 2027 (estimated)
Last update
Oct 30, 2026

Study contacts

Fernando C Maluf, MD
study chair · Brazilian Clinical Research Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Darolutamide · Leuprolide

Start the discussion